BXRX | Baudax Bio
Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. We are committed to bringing clinically meaningful therapeutic options to patients, health care providers, and payers, such as ANJESO® (meloxicam) injection, which was approved by the U.S. Food and Drug Administration (FDA) in February 2020. ANJESO is indicated for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Because of delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required. We believe we can create value for healthcare providers, patients and shareholders through our portfolio of products, which also includes a robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities which align with our core acute care focus.
490 Lapp Road
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.